Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.
Simplified radiation therapy for lung cancer reduces severe side effects while preserving cure rates, especially when combined with immunotherapy.
This large real-world multicenter study (n=946 LS-SCLC) demonstrates that CTV omission from radiation planning preserves oncologic efficacy while meaningfully reducing severe radiation toxicity. Particularly notable is the striking survival improvement with CTV omission in patients receiving concurrent immunotherapy, with OS not reached versus 26.9 months in the standard CTV arm—a finding that may reshape practice pending prospective confirmation.
What the study was
- Study design
- Large-scale multicenter propensity-score-matched observational study
- Population
- Adults with limited-stage SCLC treated at multiple Chinese cancer centers (n=946; matched n=265/group, Feb 2016–Feb 2025)
- Sample size
- 946
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Radiotherapy and Oncology
Why it surfaced
Large multicenter n=946 real-world study; CTV omission reduces severe toxicity without efficacy loss; striking immunotherapy interaction (OS not reached vs 26.9 months) warrants prospective validation; directly practice-relevant for radiation oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.